Personal tools

Sponsorname

Your company could advertise here

www.fla-consulting.eu

Document:GBR Directive 2001/20/EC 04-Apr-2001

From GxPlex

Revision as of 14:15, 16 July 2026 by GxPlexBot (talk | contribs) (Remove static References table, superseded by live #ask in Template:DocumentData (GxPlexBot))
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to: navigation, search


Document information
Reference GBR Directive 2001/20/EC 04-Apr-2001
Validity area GBR
Scope(s) HM
Document name Directive 2001/20/EC
Version / Revision 04-Apr-2001
Status Current
Document type Legal act
Language(s) EN
Description DIRECTIVE 2001/20/EC OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL - of 4 April 2001

on the approximation of the laws, regulations and administrative provisions of the Member States relating to the implementation of good clinical practice in the conduct of clinical trials on medicinal products for human use

The European Directive (2001/20/EC) no longer applies in the UK. The Medicines for Human Use (Clinical Trials) (Amendment) (EU Exit) Regulations amend the Medicines for Human Use (Clinical Trials) Regulations 2004 to enable the MHRA to operate as a regulator outside the EU.

Official source Official link
Restricted access No
Submitted by Florian Adragna
Contributors

References

 ScopeDocument partLanguagePreview
GBR Directive 2001/20/EC 04-Apr-2001 Article 10 (b)-001HMArticle 10 (b)ENConduct of a clinical trial

[…]

(b)without prejudice to point (a), in the light of the circumstances, notably the occurrence of any new event relating…
GBR Directive 2001/20/EC 04-Apr-2001 Article 10 (b)-002HMArticle 10 (b)ENConduct of a clinical trial

[…]

(b)without prejudice to point (a), in the light of the circumstances, notably the occurrence of any new event relating…
GBR Directive 2001/20/EC 04-Apr-2001 Article 10 (c)HMArticle 10 (c)ENConduct of a clinical trial

[…]

(c)within 90 days of the end of a clinical trial the sponsor shall notify the competent authorities of the Member Stat…
GBR Directive 2001/20/EC 04-Apr-2001 Article 16HMArticle 16ENNotification of adverse events 1. The investigator shall report all serious adverse events immediately to the sponsor except for those that the protoc…
GBR Directive 2001/20/EC 04-Apr-2001 Article 17HMArticle 17ENNotification of serious adverse reactions 1.(a)The sponsor shall ensure that all relevant information about suspected serious unexpected adverse reac…
GBR Directive 2001/20/EC 04-Apr-2001 Article 2 (l)HMArticle 2 (l)EN(l)‘inspection’: the act by a competent authority of conducting an official review of documents, facilities, records, quality assurance arrangements, …
GBR Directive 2001/20/EC 04-Apr-2001 Article 2 (m)HMArticle 2 (m)EN(m)‘adverse event’: any untoward medical occurrence in a patient or clinical trial subject administered a medicinal product and which does not necessa…
GBR Directive 2001/20/EC 04-Apr-2001 Article 2 (n)HMArticle 2 (n)EN(n)‘adverse reaction’: all untoward and unintended responses to an investigational medicinal product related to any dose administered;…
GBR Directive 2001/20/EC 04-Apr-2001 Article 2 (o)HMArticle 2 (o)EN(o)‘serious adverse event or serious adverse reaction’: any untoward medical occurrence or effect that at any dose results in death, is life-threateni…
GBR Directive 2001/20/EC 04-Apr-2001 Article 2 (p)HMArticle 2 (p)EN(p)‘unexpected adverse reaction’: an adverse reaction, the nature or severity of which is not consistent with the applicable product information (e.g.…
GBR Directive 2001/20/EC 04-Apr-2001 Article 2 (a)HMArticle 2 (a)ENDefinitions

For the purposes of this Directive the following definitions shall apply:

(a)‘clinical trial’: any investigation in human subjects intend…
GBR Directive 2001/20/EC 04-Apr-2001 Article 2 (c)HMArticle 2 (c)EN(c)‘non-interventional trial’: a study where the medicinal product(s) is (are) prescribed in the usual manner in accordance with the terms of the mark…
GBR Directive 2001/20/EC 04-Apr-2001 Article 3HMArticle 3ENProtection of clinical trial subjects

[…] 2. A clinical trial may be undertaken only if, in particular: […]

(f) provision has been made for insurance …